Transdermal hormone therapy and the risk of stroke and venous thrombosis

References

• Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Oger E, Plu-Bureau G, et al Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428–432
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Conard J, et al Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemos 2006;4:1259–1265
   PubMed Web of Science ®Google Scholar
• Straczek C, Oger E, Yon de Jonage-Canonico MB, et al Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495–3500
   PubMed Web of Science ®Google Scholar
• Canonico M, Fourier A, Carcaillon L, et al Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340–345
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemos 2010;March 4. Epub ahead of print
   Google Scholar
• Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI, and C-reactive protein – a cross-sectional population survey. Thromb Haemost 2001;86:550–556
   PubMed Web of Science ®Google Scholar
• Post MS, Christella M, Thomassen LG, et al Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscl Thromb Vasc Biol 2003;23:1116–1121
   PubMed Web of Science ®Google Scholar
• Løkkegaard E, Jovanovic Z, Heitmann BL, et al Increased risk of stroke in hypertensive women using hormone therapy. Analyses based on the Danish Nurse Study. Arch Neurol 2003;60:1379–1384
   PubMed Web of Science ®Google Scholar
• Li C, Engström G, Hedblad B, Berglund G, Janzon L. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas 2006;54:11–18
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–866
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RL. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243–1249
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, Limacher M, et al Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673–2684
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1707–1712
   Web of Science ®Google Scholar
• Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425–2434
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–1477
   PubMed Web of Science ®Google Scholar
• Gavaler JS. Thoughts on individualizing hormone replacement therapy based on the postmenopausal health disparities study data. J Women's Health 2003;12:757–768
   PubMed Web of Science ®Google Scholar
• Kraemer GR, Kraemer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane VD. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 2003;79:534–542
   PubMed Web of Science ®Google Scholar
• Bukowska H, Stanosz S, Zochowska E, et al Does the type of hormone replacement therapy affect lipoprotein(a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005;54:72–78
   PubMed Web of Science ®Google Scholar
• Ropponen A, Aittomaki K, Vihma V, Tikkanen MJ, Ylikorkala O. Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. J Clin Endocrinol Metab 2005;90:3431–3434
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619–625
   PubMed Web of Science ®Google Scholar